2020
Chapter 20 Phosphorus homeostasis and related disorders
Carpenter T, Bergwitz C, Insogna K. Chapter 20 Phosphorus homeostasis and related disorders. 2020, 469-507. DOI: 10.1016/b978-0-12-814841-9.00020-8.ChaptersEndocrine fibroblast growth factorsSupply of phosphateComplex regulatory systemMolecular regulationRegulatory signalsFibroblast growth factorIntricate mechanismsPhosphate transferRegulatory systemNovel targetBone biologyMammalian boneCritical roleDistinct classesGrowth factorSkeletal mineralizationCentral rolePhosphate metabolismPrincipal mediatorEndocrine organClasses of transportersPhosphorus homeostasisBiologyTransportersLocal milieu
2016
Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label phase 2 study
Linglart A, Carpenter T, Imel E, Boot A, Högler W, Padidela R, Hoff W, Whyte M, Chen C, Skrinar A, Agarwal S, San Martin J, Portale A. Effect of KRN23, a fully human anti-FGF23 monoclonal antibody, on rickets in children with X-linked hypophosphatemia (XLH): 40-week interim results from a randomized, open-label phase 2 study. Annales D Endocrinologie 2016, 77: 440. DOI: 10.1016/j.ando.2016.07.547.Peer-Reviewed Original ResearchRickets Severity ScoreAdverse eventsQ2W dosingXLH childrenSerum PiMost treatment-related adverse eventsOpen-label phase 2 studyTransient injection site reactionsTreatment-related adverse eventsPhase 2 studySerious adverse eventsInjection site reactionsSerum phosphate levelsRadiographic Global ImpressionSerum Pi concentrationSerum iPTHUrine calciumRenal ultrasoundSite reactionsCare treatmentGlobal ImpressionSeverity scoreKRN23Phosphorus homeostasisShort stature